COMPASS Pathways PLC

The Current Landscape Of Mental Health Is Failing Patients Mental health treatments often fail many patients, leaving them struggling to find relief and support. Patients in this category are often considered “treatment-resistant,” where multiple therapies have limited or no...

The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. Slated to take effect starting in 2024, the new temporary CPT III code marks an important step toward broader access...

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa. The trial will compare the effects of 25 mg and 1 mg of COMP360 (...

Compass Pathways (NASDAQ: CMPS) announced its financial results for the first quarter of 2022, which ended March 31. Q1 Results For the first three months of the year, net loss was $21.2 million, or $0.50 loss per share. For comparison, net loss in the same period of 2021 was $12.7 million or...

Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults. The study, named Psilaut, is being co-sponsored by the...

COMPASS Pathways plc (NASDAQ: CMPS) has announced the formation of a long-term partnership with the South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. The aim of this collaboration is to launch The...

Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has...

Get into psychedelics now. That's according to Michael "Zappy" Zapolin, a former Bear Stearns VP turned psychedelics advocate and filmmaker. Zappy's call to invest comes as psychedelics make a continued push towards credibility on the medical, legal and business...